Features:
The Siro™ drug eluting stent sets the bar for other stents to follow. It combines the U.S. patented Direct-Stent® design with the proven successful Sirolimus drug to reduce tissue ingrowth and proliferation leading to reduced restenosis.
Proven successful Sirolimus drug
Strength of a hybrid cell stent design
Premounted as low as 0.9 mm
Semi-compliant balloon material
Direct-Stent® U.S. patented platform
Clinically proven biostable polymer